Northfield Laboratories, Inc., has completed a Phase III trial for Polyheme, its oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss and has applied for the Federal Drug Administration's Fast-Track status.
Northfield has been researching blood substitutes for more than twenty years posting over $170 million in losses in its pursuit of Dracula's Holy Grail.
Northfield's annual meeting is September 20, 2006. A recent news release linked here.
Northfield's website linked here.
An interesting article linked here.
Monday, August 28, 2006
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment